RE:RE:RE:It's July 10th --- 2nd Qtr Ended 10 Days AgoMaybe, but TLT never had the cash on hand to get things moving like we'd all like to see. So last year they did a financing that most of us didn't like but hopefully it's enough to see the Ph2 through to at least 50 patients. 40/50 complete response at six months should get things moving in the right direction. And lets not forget who we're going up against. Probably 80% of Mercks' $200 billion valuation is due to Keytruda which comes off patent in 8 years. Lung cancer in 2018 was an $18 billion market.
Mercks Keytruda Pandora wrote: From a business management point-of-view Canada is probably more noted for being a follower rather than a leader. I don't really notice the TLT team being out at the front of the line setting the great example as to how to make things happen!
vestor111 wrote: This is why I have suggested to discuss other things - like the prep work needed to support a US trial and a CA trial simultaneously. How many controllers/workstations have been built. DFOC inventory...ANYTHING!
Or how about a description of the work flow with the model stimulator, with the controller platform and how the Docs/techs interact with the system before during and after the procedure.
Or how about noting what is going on at RPCCC? Or Leiden U? With maybe a clarification of how they see this kind of work evolving into a licensing/partnering relationship.
I think you might be closer to the dish of mush we get served but I hope not.
Or how about while we wait...a spotlight on all of Dr Sherri's efforts.
Silly me.